IFNG and Primary hemophagocytic lymphohistiocytosis: Emapalumab (Swedish Orphan Biovitrum) is a human IgG1 raised against interferon gamma, approved for treatment of primary hemophagocytic lymphohistiocytosis, and evaluated in a Phase 2/3 in patients with COVID-19 (NCT04324021).